Keyphrases
Non-alcoholic Fatty Liver Disease (NAFLD)
100%
Diabetes Prevention Program
100%
Hepatic Steatosis
40%
High-density Lipoprotein Cholesterol (HDL-C)
20%
Improved Outcomes
20%
Liver Injury
20%
Laboratory Values
20%
Per-protocol
20%
Alanine Aminotransferase
20%
Clinical Laboratory
20%
Patient-completed
20%
Lipid Metabolism
20%
Lose Weight
20%
Clinical Trial Registry
20%
Pre-diabetes (pre-DM)
20%
Aspartate Aminotransferase
20%
Metabolic Features
20%
Metabolic Comorbidities
20%
Low-density Lipoprotein
20%
Medical Comorbidity
20%
Liver Enzymes
20%
Liver Lipid
20%
Change in Weight
20%
Nonalcoholic Fatty Liver Disease Activity Score
20%
Incident Type 2 Diabetes Mellitus
20%
Lifestyle Modification Program
20%
Medicine and Dentistry
Nonalcoholic Fatty Liver
100%
Diabetes Prevention
100%
Fatty Liver
33%
Comorbidity
33%
Lifestyle Modification
16%
Clinical Trial
16%
Maturity Onset Diabetes of the Young
16%
Alanine Aminotransferase
16%
Aspartate Aminotransferase
16%
Liver Injury
16%
Fibrosis
16%
Lipid Metabolism
16%
High-Density Lipoprotein
16%
Impaired Glucose Tolerance
16%
Low-Density Lipoprotein
16%
Liver Enzyme
16%
Pharmacology, Toxicology and Pharmaceutical Science
Nonalcoholic Fatty Liver
100%
Fatty Liver
33%
Comorbidity
33%
Fibrosis
16%
Liver Injury
16%
Clinical Trial
16%
Aspartate Aminotransferase
16%
Alanine Aminotransferase
16%
High Density Lipoprotein
16%
Impaired Glucose Tolerance
16%
Liver Enzyme
16%
Low Density Lipoprotein
16%
Non Insulin Dependent Diabetes Mellitus
16%